Vaccine impact: Benefits for human health

Vaccine

Volumn 34, Issue 52, 2016, Pages 6707-6714

  Doherty, Mark ^a   Buchy, Philippe ^b   Standaert, Baudouin ^a   Giaquinto, Carlo ^c   Prado Cohrs, David ^d  

^a GSK   (Belgium)

^b GSK Vaccines   (Singapore)

^c UNIVERSITY OF PADOVA   (Italy)

^d Universidad Francisco Marroquin   (Guatemala)

Author keywords

Cost; Effectiveness; Health economics; Herd protection; Impact; Vaccine

Indexed keywords

VACCINE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG SURVEILLANCE PROGRAM; HEALTH; HEALTH CARE PERSONNEL; HEALTH ECONOMICS; HUMAN; IMMUNIZATION; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SOCIETY; COMMUNICABLE DISEASE; DISEASE TRANSMISSION; IMMUNOLOGY; PREVENTION AND CONTROL; VACCINATION;

COMMUNICABLE DISEASES; DISEASE TRANSMISSION, INFECTIOUS; HUMANS; VACCINATION; VACCINES;

EID: 85001104550     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.10.025     Document Type: Article

References (94)

1. [1] Foster, E., The statistic evidences of the value of vaccination to the human race, past, present and future. JAMA XXVII (1896), 671–677.
2. [2] Schwartz, J.L., New media, old messages: themes in the history of vaccine hesitancy and refusal. Virtual Mentor 14 (2012), 50–55, 10.1001/virtualmentor.2012.14.1.mhst1-1201.
3. [3] Barrett, S., Eradication versus control: the economics of global infectious disease policies. Bull World Health Organ 82 (2004), 683–688.
4. [4] Bloom, D., Canning, D., Weston, M., The value of vaccination. World Econ 6 (2005), 15–39.
5. [5] Gessner, B.D., Feikin, D.R., Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine 32 (2014), 3133–3138, 10.1016/j.vaccine.2014.04.019.
6. [6] Halloran, M.E., Struchiner, C.J., Study designs for dependent happenings. Epidemiology 2 (1991), 331–338.
7. [7] Fine, P., Eames, K., Heymann, D.L., “Herd immunity”: a rough guide. Clin Infect Dis 52 (2011), 911–916, 10.1093/cid/cir007.
8. [8] Plans-Rubió, P., Evaluation of the establishment of herd immunity in the population by means of serological surveys and vaccination coverage. Hum Vaccin Immunother 8 (2012), 184–188, 10.4161/hv.18444.
9. [9] Hanquet, G., Valenciano, M., Simondon, F., Moren, A., Vaccine effects and impact of vaccination programmes in post-licensure studies. Vaccine 31 (2013), 5634–5642, 10.1016/j.vaccine.2013.07.006.
10. [10] Lieu, T.A., Ray, G.T., Black, S.B., Butler, J.C., Klein, J.O., Breiman, R.F., et al. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children. JAMA 283 (2000), 1460–1468.
11. [11] Weinstein, M.C., Stason, W.B., Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 296 (1977), 716–721, 10.1056/NEJM197703312961304.
12. [12] Melliez, H., Levybruhl, D., Boelle, P.Y., Dervaux, B., Baron, S., Yazdanpanah, Y., Cost and cost-effectiveness of childhood vaccination against rotavirus in France. Vaccine 26 (2008), 706–715, 10.1016/j.vaccine.2007.11.064.
13. [13] Demarteau, N., Standaert, B., Modelling the economic value of cross- and sustained-protection in vaccines against cervical cancer. J Med Econ 13 (2010), 324–338, 10.3111/13696998.2010.490481.
14. [14] Talbird, S.E., Taylor, T.N., Caporale, J., Ismaila, A.S., Gomez, J., Residual economic burden of Streptococcus pneumoniae- and nontypeable Haemophilus influenzae-associated disease following vaccination with PCV-7: a multicountry analysis. Vaccine 28:Suppl 6 (2010), G14–G22, 10.1016/j.vaccine.2010.06.080.
15. [15] Beutels, P., Edmunds, W.J., Antoñanzas, F., De Wit, G.A., Evans, D., Feilden, R., et al. Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis. Pharmacoeconomics 20 (2002), 1–7.
16. [16] Demarteau, N., Breuer, T., Standaert, B., Selecting a mix of prevention strategies against cervical cancer for maximum efficiency with an optimization program. Pharmacoeconomics 30 (2012), 337–353, 10.2165/11591560-000000000-00000.
17. [17] Standaert, B.A., Curran, D., Postma, M.J., Budget constraint and vaccine dosing: a mathematical modelling exercise. Cost Eff Resour Alloc, 12, 2014, 3, 10.1186/1478-7547-12-3.
18. [18] Connolly, M.P., Topachevskyi, O., Standaert, B., Ortega, O., Postma, M., The impact of rotavirus vaccination on discounted net tax revenue in Egypt: a government perspective analysis. Pharmacoeconomics 30 (2012), 681–695, 10.2165/11597750-000000000-00000.
19. [19] Kotsopoulos, N., Connolly, M.P., Postma, M.J., Hutubessy, R.C.W., Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation. Vaccine 31 (2013), 5430–5434, 10.1016/j.vaccine.2013.09.002.
20. [20] Neumann, P.J., Cohen, J.T., Weinstein, M.C., Updating cost-effectiveness–the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 371 (2014), 796–797, 10.1056/NEJMp1405158.
21. [21] Walker, D.G., Hutubessy, R., Beutels, P., WHO Guide for standardisation of economic evaluations of immunization programmes. Vaccine 28 (2010), 2356–2359, 10.1016/j.vaccine.2009.06.035.
22. [22] Marseille, E., Larson, B., Kazi, D.S., Kahn, J.G., Rosen, S., Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ 93 (2015), 118–124, 10.2471/BLT.14.138206.
23. [23] Standaert, B., Ethgen, O., Emerson, R., Postma, M., Mauskopf, J., Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?. Adv Ther 31 (2014), 1095–1108, 10.1007/s12325-014-0160-6.
24. [24] Newall, A.T., Jit, M., Hutubessy, R., Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines. Pharmacoeconomics 32 (2014), 525–531, 10.1007/s40273-014-0162-x.
25. [25] Chisholm, D., Evans, D., Economic evaluation in health: saving money or improving care?. J Med Econ 10 (2007), 325–337.
26. [26] Drummond, M., Jönsson, B., Rutten, F., The role of economic evaluation in the pricing and reimbursement of medicines. Health Policy 40 (1997), 199–215.
27. [27] Scarbrough Lefebvre, C.D., Terlinden, A., Standaert, B., Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccin Immunother 11 (2015), 2142–2157, 10.1080/21645515.2015.1052196.
28. [28] Bauch, C.T., Anonychuk, A.M., Van Effelterre, T., Pham, B.Z., Merid, M.F., Incorporating herd immunity effects into cohort models of vaccine cost-effectiveness. Med Decis Making 29 (2009), 557–569, 10.1177/0272989X09334419.
29. [29] Standaert, B., Van de Mieroop, E., Nelen, V., Exploring the potential impact of rotavirus vaccination on work absenteeism among female administrative personnel of the City of Antwerp through a retrospective database analysis. BMJ Open, 5, 2015, e007453, 10.1136/bmjopen-2014-007453.
30. [30] Palmu, A.A., Jokinen, J., Nieminen, H., Rinta-Kokko, H., Ruokokoski, E., Puumalainen, T., et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3–4 trial. Lancet Infect Dis 14 (2014), 205–212, 10.1016/S1473-3099(13)70338-4.
31. [31] Standaert, B., Alwan, A., Strens, D., Raes, M., Postma, M.J., Improvement in hospital Quality of Care (QoC) after the introduction of rotavirus vaccination: an evaluation study in Belgium. Hum Vaccin Immunother 11 (2015), 2266–2273, 10.1080/21645515.2015.1029212.
32. [32] Roed, C., Omland, L.H., Skinhoj, P., Rothman, K.J., Sorensen, H.T., Obel, N., Educational achievement and economic self-sufficiency in adults after childhood bacterial meningitis. JAMA 309 (2013), 1714–1721, 10.1001/jama.2013.3792.
33. [33] Eppig, C., Fincher, C.L., Thornhill, R., Parasite prevalence and the worldwide distribution of cognitive ability. Proc Biol Sci 277 (2010), 3801–3808, 10.1098/rspb.2010.0973.
34. [34] Brisson, M., Laprise, J.-F., Drolet, M., Van de Velde, N., Franco, E.L., Kliewer, E.V., et al. Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study. Vaccine 31 (2013), 3863–3871, 10.1016/j.vaccine.2013.06.064.
35. [35] Tilson, L., Thornton, L., O'Flanagan, D., Johnson, H., Barry, M., Cost effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health 18 (2008), 275–282, 10.1093/eurpub/ckm123.
36. [36] Smith, R.D., Keogh-Brown, M.R., Macroeconomic impact of pandemic influenza and associated policies in Thailand, South Africa and Uganda. Influenza Other Respir Viruses 7:Suppl 2 (2013), 64–71, 10.1111/irv.12083.
37. [37] Bloom, D., Mahal, A., Does the AIDS epidemic threaten economic growth?. J Econom 77 (1997), 105–124.
38. [38] Jit, M., Hutubessy, R., Png, M.E., Sundaram, N., Audimulam, J., Salim, S., et al. The broader economic impact of vaccination: reviewing and appraising the strength of evidence. BMC Med, 13, 2015, 209, 10.1186/s12916-015-0446-9.
39. [39] Jit, M., Mibei, W., Discounting in the evaluation of the cost-effectiveness of a vaccination programme: a critical review. Vaccine 33 (2015), 3788–3794, 10.1016/j.vaccine.2015.06.084.
40. [40] Smith, S., Environmental economics. 2011, Oxford University Press, A very short introduction. Great Britain.
41. [41] Toumi, M., Ricciardi, W., The economic value of vaccination: why prevention is wealth. J Market Access Health Policy, 3, 2015, 29204, 10.3402/jmahp.v3.29204.
42. [42] Taylor, D.C.A., Pawar, V., Kruzikas, D., Gilmore, K.E., Pandya, A., Iskandar, R., et al. Methods of model calibration: observations from a mathematical model of cervical cancer. Pharmacoeconomics 28 (2010), 995–1000, 10.2165/11538660-000000000-00000.
43. [43] Eddy, D.M., Hollingworth, W., Caro, J.J., Tsevat, J., McDonald, K.M., Wong, J.B., et al. Model transparency and validation: a report of the ISPOR-SMDM modeling good research practices task force–7. Value Health 15 (2012), 843–850, 10.1016/j.jval.2012.04.012.
44. [44] Kotsopoulos, N., Connolly, Is the gap between micro- and macroeconomic assessments in health care well understood? The case of vaccination and potential remedies. J Market Access Health Policy, 2, 2014, 1.
45. [45] Smith A. An inquiry into the nature and causes of the wealth of nations. In: Cannan E, editor. 5th ed. London: Methuen & Co., Ltd.; 1776.
46. [46] Lynn, R., Meisenberg, G., Mikk, J., Williams, A., National IQs predict differences in scholastic achievement in 67 countries. J Biosoc Sci 39 (2007), 861–874, 10.1017/S0021932007001964.
47. [47] Pietschnig, J., Voracek, M., One century of global IQ gains: a formal meta-analysis of the Flynn effect (1909–2013). Perspect Psychol Sci 10 (2015), 282–306, 10.1177/1745691615577701.
48. [48] Borba, R.C.N., Vidal, V.M., Moreira, L.O., The re-emergency and persistence of vaccine preventable diseases. An Acad Bras Cienc 87 (2015), 1311–1322, 10.1590/0001-3765201520140663.
49. [49] Rocha, H.A.L., Correia, L.L., Campos, J.S., Silva, A.C., Andrade, F.O., Silveira, D.I., et al. Factors associated with non-vaccination against measles in northeastern Brazil: clues about causes of the 2015 outbreak. Vaccine 33 (2015), 4969–4974, 10.1016/j.vaccine.2015.07.027.
50. [50] Winter, K., Glaser, C., Watt, J., Harriman, K., Centers for Disease Control and Prevention (CDC). Pertussis epidemic–California, 2014. MMWR Morb Mortal Wkly Rep 63 (2014), 1129–1132.
51. [51] Avila-Aguero, M.L., Camacho-Badilla, K., Ulloa-Gutierrez, R., Measles outbreaks: what does it represent for the elimination strategy in the region of the Americas? A call for the action. Expert Rev Vaccines 14 (2015), 1043–1045, 10.1586/14760584.2015.1055325.
52. [52] Begg, N., Miller, E., Role of epidemiology in vaccine policy. Vaccine 8 (1990), 180–189.
53. [53] Atkinson, W.L., Orenstein, W.A., Krugman, S., The resurgence of measles in the United States, 1989–1990. Annu Rev Med 43 (1992), 451–463, 10.1146/annurev.me.43.020192.002315.
54. [54] Gurgel, R.G., Bohland, A.K., Vieira, S.C.F., Oliveira, D.M.P., Fontes, P.B., Barros, V.F., et al. Incidence of rotavirus and all-cause diarrhea in northeast Brazil following the introduction of a national vaccination program. Gastroenterology 137 (2009), 1970–1975, 10.1053/j.gastro.2009.07.046.
55. [55] Correia, J.B., Patel, M.M., Nakagomi, O., Montenegro, F.M.U., Germano, E.M., Correia, N.B., et al. Effectiveness of monovalent rotavirus vaccine (Rotarix) against severe diarrhea caused by serotypically unrelated G2P[4] strains in Brazil. J Infect Dis 201 (2010), 363–369, 10.1086/649843.
56. [56] Velasquez, D.E., Parashar, U.D., Jiang, B., Strain diversity plays no major role in the varying efficacy of rotavirus vaccines: an overview. Infect Genet Evol 28 (2014), 561–571, 10.1016/j.meegid.2014.10.008.
57. [57] Suk, J.E., Semenza, J.C., Future infectious disease threats to Europe. Am J Public Health 101 (2011), 2068–2079, 10.2105/AJPH.2011.300181.
58. [58] Glanz, J.M., McClure, D.L., Magid, D.J., Daley, M.F., France, E.K., Salmon, D.A., et al. Parental refusal of pertussis vaccination is associated with an increased risk of pertussis infection in children. Pediatrics 123 (2009), 1446–1451, 10.1542/peds.2008-2150.
59. [59] Suk, J.E., Lopalco, P., Pastore Celentano, L., Hesitancy, trust and individualism in vaccination decision-making. PLoS Curr, 25(Feb), 2015, 7, 10.1371/currents.outbreaks.49dba84ad4146de33706b1f131d7caa3.
60. [60] Miller, E., Potential and existing impact of vaccines on disease epidemiology. Bloom, B.R., Lambert, P.H., (eds.) The vaccine book, 2003, Academic Press, 37–40.
61. [61] Aaby, P., Bhuiya, A., Nahar, L., Knudsen, K., de Francisco, A., Strong, M., The survival benefit of measles immunization may not be explained entirely by the prevention of measles disease: a community study from rural Bangladesh. Int J Epidemiol 32 (2003), 106–116.
62. [62] Fine, P.E., Herd immunity: history, theory, practice. Epidemiol Rev 15 (1993), 265–302.
63. [63] Esteves, K., Safety of oral poliomyelitis vaccine: results of a WHO enquiry. Bull World Health Organ 66 (1988), 739–746.
64. [64] Preblud, S.R., Orenstein, W.A., Bart, K.J., Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis 3 (1984), 505–509.
65. [65] Preblud, S.R., Age-specific risks of varicella complications. Pediatrics 68 (1981), 14–17.
66. [66] Charloner-Larsson G. Training manual on the critical regulatory function for vaccines: evaluation of clinical performance through authorized clinical trials: prepared for national regulatory authorities of vaccine-procuring and vaccine-producing countries. WHO/V&B/03.12; 2003.
67. [67] Centers for Disease Control and Prevention, Manual for the surveillance of vaccine-preventable diseases. 2008, Centers for Disease Control and Prevention, Atlanta, GA.
68. [68] Haber, M., Longini, I.M., Halloran, M.E., Measures of the effects of vaccination in a randomly mixing population. Int J Epidemiol 20 (1991), 300–310.
69. [69] Beasley, R.P., Trepo, C., Stevens, C.E., Szmuness, W., The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol 105 (1977), 94–98.
70. [70] Edmunds, W.J., Medley, G.F., Nokes, D.J., O'Callaghan, C.J., Whittle, H.C., Hall, A.J., Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117 (1996), 313–325.
71. [71] Shapiro, C.N., Epidemiology of hepatitis B. Pediatr Infect Dis J 12 (1993), 433–437.
72. [72] Poovorawan, Y., Chongsrisawat, V., Theamboonlers, A., Leroux-Roels, G., Kuriyakose, S., Leyssen, M., et al. Evidence of protection against clinical and chronic hepatitis B infection 20°years after infant vaccination in a high endemicity region. J Viral Hepat 18 (2011), 369–375, 10.1111/j.1365-2893.2010.01312.x.
73. [73] Iwai, M., Takizawa, T., Nakayama, T., Matsuura, K., Yoshida, H., Hasegawa, S., et al. Evaluation of a two-dose administration of live oral poliovirus vaccine for wild and virulent vaccine-derived poliovirus type 1, 2, 3 strains in Japan. Scand J Infect Dis 40 (2008), 247–253, 10.1080/00365540701596003.
74. [74] Paulke-Korinek, M., Kundi, M., Rendi-Wagner, P., de Martin, A., Eder, G., Schmidle-Loss, B., et al. Herd immunity after two years of the universal mass vaccination program against rotavirus gastroenteritis in Austria. Vaccine 29 (2011), 2791–2796, 10.1016/j.vaccine.2011.01.104.
75. [75] Tate, J.E., Panozzo, C.A., Payne, D.C., Patel, M.M., Cortese, M.M., Fowlkes, A.L., et al. Decline and change in seasonality of US rotavirus activity after the introduction of rotavirus vaccine. Pediatrics 124 (2009), 465–471, 10.1542/peds.2008-3528.
76. [76] Curns, A.T., Steiner, C.A., Barrett, M., Hunter, K., Wilson, E., Parashar, U.D., Reduction in acute gastroenteritis hospitalizations among US children after introduction of rotavirus vaccine: analysis of hospital discharge data from 18 US states. J Infect Dis 201 (2010), 1617–1624, 10.1086/652403.
77. [77] Yen, C., Armero Guardado, J.A., Alberto, P., Rodriguez Araujo, D.S., Mena, C., Cuellar, E., et al. Decline in rotavirus hospitalizations and health care visits for childhood diarrhea following rotavirus vaccination in El Salvador. Pediatr Infect Dis J 30 (2011), S6–S10, 10.1097/INF.0b013e3181fefa05.
78. [78] Buttery, J.P., Lambert, S.B., Grimwood, K., Nissen, M.D., Field, E.J., Macartney, K.K., et al. Reduction in rotavirus-associated acute gastroenteritis following introduction of rotavirus vaccine into Australia's National Childhood vaccine schedule. Pediatr Infect Dis J 30 (2011), S25–S29, 10.1097/INF.0b013e3181fefdee.
79. [79] Patel, M.M., Steele, D., Gentsch, J.R., Wecker, J., Glass, R.I., Parashar, U.D., Real-world impact of rotavirus vaccination. Pediatr Infect Dis J 30 (2011), S1–S5, 10.1097/INF.0b013e3181fefa1f.
80. [80] Hull, J.J., Teel, E.N., Kerin, T.K., Freeman, M.M., Esona, M.D., Gentsch, J.R., et al. United States rotavirus strain surveillance from 2005 to 2008: genotype prevalence before and after vaccine introduction. Pediatr Infect Dis J 30 (2011), S42–S47, 10.1097/INF.0b013e3181fefd78.
81. [81] Kirkwood, C.D., Boniface, K., Barnes, G.L., Bishop, R.F., Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia. Pediatr Infect Dis J 30 (2011), S48–S53, 10.1097/INF.0b013e3181fefd90.
82. [82] Carvalho-Costa, F.A., Volotão, E.de M., de Assis, R.M.S., Fialho, A.M., de Andrade, J.da S.R., Rocha, L.N., et al. Laboratory-based rotavirus surveillance during the introduction of a vaccination program, Brazil, 2005–2009. Pediatr Infect Dis J 30 (2011), S35–S41, 10.1097/INF.0b013e3181fefd5f.
83. [83] Holt, E.A., Boulos, R., Halsey, N.A., Boulos, L.M., Boulos, C., Childhood survival in Haiti: protective effect of measles vaccination. Pediatrics 85 (1990), 188–194.
84. [84] Kabir, Z., Long, J., Reddaiah, V.P., Kevany, J., Kapoor, S.K., Non-specific effect of measles vaccination on overall child mortality in an area of rural India with high vaccination coverage: a population-based case-control study. Bull World Health Organ 81 (2003), 244–250.
85. [85] Aaby, P., Kollmann, T.R., Benn, C.S., Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. Nat Immunol 15 (2014), 895–899, 10.1038/ni.2961.
86. [86] Mina, M.J., Metcalf, C.J.E., de Swart, R.L., Osterhaus, A.D.M.E., Grenfell, B.T., Long-term measles-induced immunomodulation increases overall childhood infectious disease mortality. Science 348 (2015), 694–699, 10.1126/science.aaa3662.
87. [87] Strebel, P.M., Papania, M., Halsey, N., Measles vaccine. Vaccines. 4th ed., 2004, Saunders Elsevier, USA, 389–440.
88. [88] Korczyńska, M.R., Paradowska-Stankiewicz, I., Rubella in Poland in 2013. Przegl Epidemiol 69 (2015), 213–218.
89. [89] Zhou, F., Shefer, A., Weinbaum, C., McCauley, M., Kong, Y., Impact of hepatitis A vaccination on health care utilization in the United States, 1996–2004. Vaccine 25 (2007), 3581–3587, 10.1016/j.vaccine.2007.01.081.
90. [90] Samandari, T., Bell, B.P., Armstrong, G.L., Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine 22 (2004), 4342–4350, 10.1016/j.vaccine.2004.04.014.
91. [91] Dagan, R., Leventhal, A., Anis, E., Slater, P., Ashur, Y., Shouval, D., Incidence of hepatitis A in Israel following universal immunization of toddlers. JAMA 294 (2005), 202–210, 10.1001/jama.294.2.202.
92. [92] Hanna, J.N., Hills, S.L., Humphreys, J.L., Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland. Med J Aust 181 (2004), 482–485.
93. [93] Van Damme, P., Van Herck, K., Effect of hepatitis A vaccination programs. JAMA 294 (2005), 246–248, 10.1001/jama.294.2.246.
94. [94] Paterson, P., Meurice, F., Stanberry, L.R., Glismann, S., Rosenthal, S.L., Larson, H.J., Vaccine hesitancy and healthcare providers. Vaccine 34 (2016), 6700–6706, 10.1016/j.vaccine.2016.10.042.